glp-1 agonist comparison chart Mapping the effectiveness and risks of receptor agonists Comparative efficacy and safety of
Description
Diabetes, Obesity & Metabolism, 20 ,
Jung, G
Acknowledgments This work was funded by the Commonwealth Fund
This can be associated with the development of neurodegenerative disorders [136]
eventually, however, the progressive dysfunction results in clinical symptoms such as fatigue, reduced exercise capacity, dyspnoea, and congestion (decompensation)
Conversely, data from clinical trials have showed an increased risk of incident heart failure with DPP4 inhibitors compared to placebo
